Eloxx Pharmaceuticals, Inc. (ELOX)

0.8800 -0.0811 (-8.44%) At close: 03:19PM EDT

Eloxx Pharmaceuticals, Inc.

480 Arsenal Way
Suite 130
Watertown, MA 02472
United States
781 577 5300
https://www.eloxxpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 18

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Sumit Aggarwal M.B.A.	President, CEO & Director	839.67k	N/A	1973
Mr. Daniel E. Geffken M.B.A.	Interim CFO, Principal Financial Officer & Principal Accounting Officer	63.96k	N/A	1957
Ms. Barbara Ryan	Investor Relations Officer	N/A	N/A	N/A
Dr. Ali Hariri M.D.	Chief Medical Officer	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.

Corporate governance

Eloxx Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.